Join us for Trevi Therapeutics virtual R&D Day, where key opinion leaders Peter Dicpinigaitis, MD and Brian Kim, MD, MTR will discuss the current treatment landscape and unmet medical need in treating patients with chronic cough and prurigo nodularis, respectively.

Trevi leadership will discuss the potential opportunity for Haduvio™ (nalbuphine ER) to be a first-in-class oral therapy for chronic cough in idiopathic pulmonary fibrosis and prurigo nodularis and the unique dual central and peripheral mechanism of action.

Trevi previously announced positive interim data from their Phase 2 CANAL trial and topline data from their Phase 2b/3 PRISM trial, where both demonstrated statistically significant results with Haduvio and no new safety signals were identified.

A live question and answer session will follow the formal presentations.